Topic Highlight
Copyright ©The Author(s) 2015.
World J Gastroenterol. Nov 21, 2015; 21(43): 12311-12321
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12311
Table 1 Drug-drug interactions between directly acting anti-hepatitis C virus directly acting antiviral and combined anti-viral therapy
Anti-HCV DAAcART not recommendedDose changes
BoceprevirAtazanavir
Darunavir/ritonavir
Efavirenz
Ritonavir
TelaprevirDarunavirEfavirenz - dose increased
Lopinavir/ritonavirto 1125 mg TDS
SimeprevirAtazanavir
Efavirenz
Darunavir/ritonavir
Nevirapine
Daclatasvir-Efavirenz - dose increased to 90 mg OD
Atazanavir and protease inhibitors - dose reduced to 30 mg OD
SofosbuvirDidanosine
Zidovudine